Johnson & Johnson, which is being touted as another major player in developing a vaccine to combat novel coronavirus is slated to begin its human trials next month i.e. July. It is important to note that the company is proceeding with its clinical trials at least two months ahead of the predicted time frame.
The vaccine candidate developed by J & J is based on adenovirus (a virus causing common cold) and the company plans to test its efficacy and safety against a placebo by dosing both younger and older volunteers. The drugmaker will check the immune safety response of the vaccine candidate in 1,045 individuals in the United States and Belgium.